PERFECT is a multicentre randomised controlled clinical trial that evaluates the efficiency of fusion magnetic resonance imaging-targeted biopsies in the transperineal (TP) versus transrectal (TR) approach in terms of the detection of significant cancers. Our study builds on the hypothesis that the TP approach for prostate biopsies has at least the same diagnostic accuracy as the TR approach, with lower morbidity. Here, we describe the clinical protocol, study population, and primary and secondary outcomes.
European urology open science. 2022 Oct 05*** epublish ***
Alae Touzani, Gaëlle Fiard, Eric Barret, Raphaële Renard-Penna, Ambroise Salin, Benjamin Pradère, François Rozet, Jean-Baptiste Beauval, Bernard Malavaud, Gianluca Giannarini, Pierre Colin, Morgan Rouprêt, Guillaume Ploussard
Urology Department, La Croix du Sud Hospital, Quint Fonsegrives, France., Department of Urology, Grenoble Alpes University Hospital, Université Grenoble Alpes, CNRS, Grenoble INP, TIMC-IMAG, Grenoble, France., Department of Urology, Institut Mutualiste Montsouris, Paris, France., AP-HP, Radiology, Pitie-Salpetriere Hospital, Sorbonne University, Paris, France., Department of Urology, Institut Universitaire du Cancer-Oncopole, Toulouse, France., Urology Unit, Santa Maria della Misericordia Academic Medical Centre, Udine, Italy., Department of Urology, Clinique La Louvière, Lille, France., GRC 5 Predictive Onco-Uro, AP-HP, Urology, Pitie-Salpetriere Hospital, Sorbonne University, Paris, France.